Avatar

PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Patients With NDMM Who Are Eligible for ASCT

By Meletios Dimopoulos 9 Videos
292 views
April 3, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Related Videos

21:05

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.4K views
17:52

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views
16:42

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views
24:35

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

617 views
15:00

New

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

Dana-Farber Cancer Institute

P. Richardson

367 views
35:27

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

635 views
26:59

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

141 views
31:53

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

740 views
15:35

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

381 views
28:20

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

684 views
17:46

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies on a …

Insights from 2023 ASH Annual Meeting

A. Jakubowiak

1.4K views
24:23

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

620 views
20:23

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

401 views
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

890 views
09:51

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

468 views
13:15

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"

2024 ASCO® Annual Meeting Insights Hub

O. Landgren

414 views
36:10

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

467 views
13:47

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

395 views
22:33

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

211 views
19:24

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - Incorpo…

Insights from 2023 ASH Annual Meeting

P. Richardson

761 views
AUTOPLAY